Epidemiology of melanoma: Is it still epidemic? What is the role of the sun, sunbeds, Vit D, betablocks, and others?

Dermatologic Therapy

Volumn 25, Issue 5, 2012, Pages 392-396

  De Giorgi, Vincenzo ^a   Gori, Alessia ^a   Grazzini, Marta ^a   Rossari, Susanna ^a   Oranges, Teresa ^a   Longo, Anna Sara ^a   Lotti, Torello ^a   Gandini, Sara ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

beta blockers; epidemiology; melanoma; sun; vitamin D

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLECALCIFEROL; ERGOCALCIFEROL; VITAMIN D; VITAMIN D RECEPTOR;

APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER SCREENING; CUTANEOUS MALIGNANT MELANOMA; CUTANEOUS MELANOMA; EPIDEMIC; HUMAN; SUN; SUN EXPOSURE; SUNBURN; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VITAMIN INTAKE;

ADRENERGIC BETA-ANTAGONISTS; DISEASE PROGRESSION; HUMANS; INCIDENCE; MELANOMA; SKIN NEOPLASMS; SUNLIGHT; SUNSCREENING AGENTS; ULTRAVIOLET RAYS; VITAMIN D; WORLD HEALTH;

EID: 84867356130     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2012.01483.x     Document Type: Article

References (31)

1. Nørgaard C, Glud M, Gniadecki R,. Are all melanomas dangerous? Acta Derm Venereol 2011: 91 (5): 499-503.
2. Metelitsa AI, Dover DC, Smylie M, de, Gara CJ, Lauzon GJ,. A population-based study of cutaneous melanoma in Alberta, Canada (1993-2002). J Am Acad Dermatol 2010: 62: 227-232.
3. Levell NJ, Beattie CC, Shuster S, Greenberg DC,. Melanoma epidemic: a midsummer night's dream? Br J Dermatol 2009: 161: 630-634.
4. Tryggvadõttir L, Gislum M, Hakulinen T, et al. Trends in the survival of patients diagnosed with malignant melanoma of the skin in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 2010: 49: 665-672.
5. Coory M, Baade P, Aitken J, Smithers M, McLeod GR, Ring I,. Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002. Cancer Causes Control 2006: 17: 21-27.
6. MacKie RM, Bray C, Vestey J, et al. Melanoma incidence and mortality in Scotland 1979-2003. Br J Cancer 2007: 96: 1772-1777.
7. Downing A, Newton-Bishop JA, Forman D,. Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993-2003. Br J Cancer 2006: 95: 91-95.
8. Montella A, Gavin A, Middleton R, Autier P, Boniol M,. Cutaneous melanoma mortality starting to change: a study of trends in Northern Ireland. Eur J Cancer 2009: 45: 2360-2366.
9. De Giorgi V, Gori A, Alfaioli B, et al. Early diagnosis for melanoma: is open access to skin cancer clinics really significant? A prospective study. Prev Med 2010: 51 (3-4): 334-335. Epub 2010 Jul 15. No abstract available.
10. Glusac EJ,. The melanoma "epidemic," a dermatopathologist's perspective. J Cutan Pathol 2011: 38 (3): 264-267. doi: 10.1111/j.1600-0560. 2010.01660.x.
11. Welch HG, Black WC,. Overdiagnosis in cancer. J Natl Cancer Inst 2010: 102: 605-613.
12. Shuster S,. Malignant melanoma: how error amplification by screening creates spurious disease. Br J Dermatol 2009: 161: S33-S39.
13. Doré JF, Chignol MC,. Tanning salons and skin cancer. Photochem Photobiol Sci 2012: 11: 30-37.
14. de Giorgi V, Gori A, Grazzini M, et al. Sun exposure and children: what do they know? An observational study in an Italian school. Prev Med 2011: 52 (2): 186-187. Epub 2010 Nov 30.
15. Héry C, Tryggvadõttir L, Sigurdsson T, et al. A melanoma epidemic in Iceland: possible influence of sunbed use. Am J Epidemiol 2010: 172 (7): 762-767. Epub 2010 Sep 2.
16. Nielsen K, Másbäck A, Olsson H, Ingvar C,. A prospective, population-based study of 40000 women regarding host factors, UV exposure and sunbed use in relation to risk and anatomic site of cutaneous melanoma. Int J Cancer 2012: 131: 706-715. doi: 10.1002/ijc.26408. [Epub ahead of print].
17. Deeb KK, Trump DL, Johnson CS,. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007: 7 (9): 684-700.
18. Ferlay J, Bray S, Pisani P, et al. GLOOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0, cancer base no. 5. Lyon: IARC Press, 2000.
19. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005: 41 (1): 45-60. Review.
20. Caini S, Gandini S, Sera F, et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. Eur J Cancer 2009: 45 (17): 3054-3063. Epub 2009 Jun 21.
21. Rosso S, Sera F, Segnan N, Zanetti R,. Sun exposure prior to diagnosis is associated with improved survival in melanoma patients: results from a long-term follow-up study of Italian patients. Eur J Cancer 2008: 44 (9): 1275-1281.
22. Nürnberg B, Schadendorf D, Gärtner B, et al. Progression of malignant melanoma is associated with reduced 25-hydroxyvitamin D serum levels. Exp Dermatol 2008: 17 (7): 627.
23. Seifert M, Rech M, Meineke V, et al. Differential biological effects of 1,25-dihydroxyvitamin D3 on melanoma cell lines in vitro. J Steroid Biochem Mol Biol 2004: 89-90: 375-379.
24. Colston K, Colston MJ, Feldman D,. 1,25-Dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981: 108: 1083-1086.
25. Gandini S, Raimondi S, Gnagnarella P, Doré JF, Maisonneuve P, Testori A,. Vitamin D and skin cancer: a meta-analysis. Eur J Cancer 2009: 45: 634-641.
26. Halsall JA, Osborne JE, Potter L, Pringle JH, Hutchinson PE,. A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma. Br J Cancer 2004: 91: 765-770.
27. Santonocito C, Capizzi R, Concolino P, et al. Association between cutaneous melanoma, Breslow thickness and vitamin D receptor BsmI polymorphism. Br J Dermatol 2007: 156 (2): 277-282.
28. Newton-Bishop JA, Beswick S, Randerson-Moor J, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009: 27 (32): 5439-5444. Epub 2009 Sep 21.
29. Yang EV, Kim SJ, Donovan EL, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 2009: 23 (2): 267-275.
30. De Giorgi V, Grazzini M, Gandini S, et al. Treatment with β-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 2011: 171 (8): 779-781.
31. Lemeshow S, Sørensen HT, Phillips G, et al. β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 2011: 20: 2273-2279. [Epub ahead of print].